- Home
- BKYI vs XRTX Comparison
BKYI vs XRTX Comparison
Compare BKYI & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- XRTX
- Stock Information
- Founded
- BKYI 1993
- XRTX 2011
- Country
- BKYI United States
- XRTX Canada
- Employees
- BKYI N/A
- XRTX N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- XRTX Pharmaceuticals and Biotechnology
- Sector
- BKYI Technology
- XRTX Health Care
- Exchange
- BKYI Nasdaq
- XRTX Nasdaq
- Market Cap
- BKYI 5.3M
- XRTX 4.4M
- IPO Year
- BKYI 1997
- XRTX N/A
- Fundamental
- Price
- BKYI $0.85
- XRTX $0.64
- Analyst Decision
- BKYI
- XRTX
- Analyst Count
- BKYI 0
- XRTX 0
- Target Price
- BKYI N/A
- XRTX N/A
- AVG Volume (30 Days)
- BKYI 13.8M
- XRTX 6.0M
- Earning Date
- BKYI 11-13-2025
- XRTX 11-14-2025
- Dividend Yield
- BKYI N/A
- XRTX N/A
- EPS Growth
- BKYI N/A
- XRTX N/A
- EPS
- BKYI N/A
- XRTX N/A
- Revenue
- BKYI $6,911,148.00
- XRTX N/A
- Revenue This Year
- BKYI $7.45
- XRTX N/A
- Revenue Next Year
- BKYI $23.29
- XRTX N/A
- P/E Ratio
- BKYI N/A
- XRTX N/A
- Revenue Growth
- BKYI N/A
- XRTX N/A
- 52 Week Low
- BKYI $0.62
- XRTX $0.62
- 52 Week High
- BKYI $3.68
- XRTX $1.79
- Technical
- Relative Strength Index (RSI)
- BKYI 53.90
- XRTX 39.13
- Support Level
- BKYI $0.73
- XRTX $0.62
- Resistance Level
- BKYI $1.97
- XRTX $0.73
- Average True Range (ATR)
- BKYI 0.13
- XRTX 0.09
- MACD
- BKYI 0.02
- XRTX -0.02
- Stochastic Oscillator
- BKYI 11.01
- XRTX 2.74
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.